<PAGE>
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(MARK ONE)
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 1998
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM __________ TO __________
Commission File Number 0-12406
IMMUNEX CORPORATION
(exact name of registrant as specified in its charter)
Washington 51-0346580
- ------------------------------- -------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
51 University Street, Seattle, WA 98101
(Address of principal executive offices)
Registrant's telephone number, including area code (206) 587-0430
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
--- ---
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Common Stock, $.01 par value 40,007,277
---------------------------- -------------------------------
Class Outstanding at November 9, 1998
<PAGE>
IMMUNEX CORPORATION
QUARTERLY REPORT ON FORM 10-Q
SEPTEMBER 30, 1998
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page No.
--------
<S> <C>
PART I. FINANCIAL INFORMATION 3
Item 1. Financial Statements:
a) Consolidated Condensed Balance Sheets -
September 30, 1998 and December 31, 1997 4
b) Consolidated Condensed Statements of Operations -
for the three-month periods ended September 30,
1998 and September 30, 1997 5
c) Consolidated Condensed Statements of Operations -
for the nine-month periods ended September 30,
1998 and September 30, 1997 6
d) Consolidated Condensed Statements of Cash Flows -
for the nine-month periods ended September 30,
1998 and September 30, 1997 7
e) Notes to Consolidated Condensed Financial
Statements 8 - 11
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 12 - 18
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 19
Item 6. Exhibits and Reports on Form 8-K 19
SIGNATURES
</TABLE>
2
<PAGE>
PART I. FINANCIAL INFORMATION
The consolidated condensed financial statements included herein have been
prepared by Immunex Corporation ("Immunex" or the "Company") without audit,
according to the rules and regulations of the Securities and Exchange
Commission. Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been omitted pursuant to such rules and regulations. The
financial statements reflect, in the opinion of management, all adjustments
(which include only normal recurring adjustments) necessary to present fairly
the financial position and results of operations as of and for the periods
indicated. The statements should be read in conjunction with the financial
statements and the notes thereto included in the Company's Annual Report on Form
10-K for the year ended December 31, 1997.
The results of operations for the nine-month period ended September 30, 1998,
are not necessarily indicative of results to be expected for the entire year
ending December 31, 1998.
3
<PAGE>
Item 1. FINANCIAL STATEMENTS
IMMUNEX CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
<TABLE>
<CAPTION>
September 30, December 31,
1998 1997
------------- ------------
(unaudited)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 71,414 $ 66,176
Marketable securities 58,978 20,364
Accounts receivable, net 17,091 17,296
Inventories 9,666 9,031
Other current assets 4,934 3,726
--------- ---------
Total current assets 162,083 116,593
Property, plant and equipment, net 89,127 73,645
Other assets 35,686 37,095
--------- ---------
$ 286,896 $ 227,333
--------- ---------
--------- ---------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 39,148 $ 30,924
Accrued compensation and related items 8,754 8,572
Current portion of long-term
obligations 4,109 3,460
Other current liabilities 2,625 2,588
--------- ---------
Total current liabilities 54,636 45,544
Long-term obligations 5,877 5,633
Shareholders' equity:
Common stock, $.01 par value 718,701 711,485
Guaranty payment receivable from AHP - (60,032)
Unrealized gain on investment 1,380 4,646
Accumulated deficit (493,698) (479,943)
--------- ---------
Total shareholders' equity 226,383 176,156
--------- ---------
$ 286,896 $ 227,333
--------- ---------
--------- ---------
</TABLE>
See accompanying notes.
4
<PAGE>
Item 1. FINANCIAL STATEMENTS (continued)
IMMUNEX CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)
<TABLE>
<CAPTION>
Three months Three months
ended ended
September 30, September 30,
1998 1997
------------- -------------
<S> <C> <C>
Revenues:
Product sales $40,125 $37,674
Royalty and contract revenue 9,051 18,287
------- -------
49,176 55,961
Operating expenses:
Cost of product sales 7,242 6,207
Research and development 26,894 28,003
Selling, general and administrative 21,593 16,489
------- -------
55,729 50,699
------- -------
Operating income (loss) (6,553) 5,262
Other income (expense):
Interest income 1,772 1,131
Interest expense (110) (150)
Other income, net 70 11
------- -------
1,732 992
------- -------
Income (loss) before income taxes (4,821) 6,254
Provision for income taxes 104 55
------- -------
Net income (loss) $(4,925) $ 6,199
------- -------
------- -------
Earnings (loss) per common share:
Basic $ (0.12) $ 0.16
------- -------
------- -------
Diluted $ (0.12) $ 0.15
------- -------
------- -------
Number of shares used for per share amounts:
Basic 39,898 39,645
------- -------
------- -------
Diluted 39,898 41,714
------- -------
------- -------
</TABLE>
See accompanying notes.
5
<PAGE>
Item 1. FINANCIAL STATEMENTS (continued)
IMMUNEX CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)
<TABLE>
<CAPTION>
Nine months Nine months
ended ended
September 30, September 30,
1998 1997
------------- -------------
<S> <C> <C>
Revenues:
Product sales $118,902 $112,534
Royalty and contract revenue 36,295 25,880
-------- --------
155,197 138,414
Operating expenses:
Cost of product sales 22,024 18,713
Research and development 90,710 78,735
Selling, general and administrative 60,810 54,388
-------- --------
173,544 151,836
-------- --------
Operating loss (18,347) (13,422)
Other income (expense):
Interest income 4,862 2,840
Interest expense (331) (466)
Other income, net 311 17
-------- --------
4,842 2,391
-------- --------
Loss before income taxes (13,505) (11,031)
Provision for income taxes 250 170
-------- --------
Net loss $(13,755) $(11,201)
-------- --------
-------- --------
Loss per common share, basic and diluted $ (0.35) $ (0.28)
-------- --------
-------- --------
Number of shares used for per share amounts 39,820 39,622
-------- --------
-------- --------
</TABLE>
See accompanying notes.
6
<PAGE>
Item 1. FINANCIAL STATEMENTS (continued)
IMMUNEX CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
<TABLE>
<CAPTION>
Nine months Nine months
ended ended
September 30, September 30,
1998 1997
------------- -------------
<S> <C> <C>
Cash flows from operating activities:
Net loss $(13,755) $(11,201)
Adjustments to reconcile net loss to net
cash provided by operating activities:
Depreciation and amortization 13,734 12,360
Cash flow impact of changes to:
Accounts receivable 205 (2,781)
Inventories 2,194 316
Accounts payable, accrued liabilities
and other current liabilities 4,849 9,129
Other current assets (1,079) (179)
-------- --------
Net cash provided by operating
activities 6,148 7,644
-------- --------
Cash flows from investing activities:
Purchases of property, plant and equipment (25,866) (6,348)
Purchases of marketable securities (68,858) (24,960)
Proceeds from sales and maturities of
marketable securities 30,906 7,862
Acquisition of product rights (5,000) -
Other (233) (1,563)
-------- --------
Net cash used in investing activities (69,051) (25,009)
-------- --------
Cash flows from financing activities:
Guaranty payments received from AHP 60,032 56,000
Proceeds from the issuance of common
stock to AHP 4,587 -
Proceeds from exercise of stock options 2,629 1,050
Other 893 179
-------- --------
Net cash provided by financing
activities 68,141 57,229
-------- --------
Net increase in cash and cash equivalents 5,238 39,864
Cash and cash equivalents, beginning of
period 66,176 23,861
-------- --------
Cash and cash equivalents, end of period $ 71,414 $ 63,725
-------- --------
-------- --------
</TABLE>
See accompanying notes.
7
<PAGE>
IMMUNEX CORPORATION
Notes to Consolidated Condensed Financial Statements
NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION
Immunex is a biopharmaceutical company that discovers, develops, manufactures
and markets human therapeutic products to treat cancer, infectious diseases and
immunological disorders.
The Company operates in a highly regulated and competitive environment. The
manufacturing and marketing of pharmaceutical products requires approval from
and is subject to ongoing oversight by the United States Food and Drug
Administration ("FDA") and by comparable agencies in other countries. Obtaining
approval for a new therapeutic product is never certain and may take several
years and involve expenditure of substantial resources. Competition in
researching, developing and marketing pharmaceutical products is intense. Any
of the technologies covering the Company's existing products or products under
development could become obsolete or diminished in value by discoveries and
developments of other organizations.
The Company's current market for sales of its pharmaceutical products is the
United States. The Company primarily uses wholesaler distributors for the sale
of its products to clinics and hospitals.
The condensed consolidated financial statements are prepared in conformity with
generally accepted accounting principles which require management estimates and
assumptions that affect the amounts reported on the financial statements and
accompanying notes. Actual results could differ from those estimates.
American Home Products Corporation ("AHP"), holds a majority interest in
Immunex, totaling approximately 54%. All references to AHP include AHP and its
various affiliates, divisions and subsidiaries.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of the Company and
its wholly owned subsidiary. All significant intercompany accounts and
transactions have been eliminated in consolidation.
CASH EQUIVALENTS
Cash equivalents consist principally of deposits in money market accounts
available on demand or securities with purchased maturities of 90 days or less.
MARKETABLE SECURITIES
Marketable securities are classified as available-for-sale and are stated at
fair value. Marketable securities consist of United States government and
corporate obligations.
8
<PAGE>
IMMUNEX CORPORATION
Notes to Consolidated Financial Statements (continued)
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED
INVENTORIES
Inventories are stated at the lower of cost, using a weighted-average method, or
market. The components of inventories are as follows (in thousands):
<TABLE>
<CAPTION>
September 30, December 31,
1998 1997
------------- ------------
<S> <C> <C>
Raw materials $1,000 $1,069
Work in process 3,820 5,377
Finished goods 4,846 2,585
------ ------
Totals $9,666 $9,031
------ ------
------ ------
</TABLE>
Finished goods inventory includes $3.1 million of finished goods inventory of
ENBREL-TM- (etanercept). The Company has identified certain risk factors that
could affect the Company's ability to commercialize ENBREL in the "Risk Factors"
section in the Company's latest Annual Report on Form 10-K filed with the
Securities and Exchange Commission. On November 2, 1998, the Company received
FDA approval to market ENBREL in the United States. ENBREL is indicated for
reduction in signs and symptoms of moderately to severely active rheumatoid
arthritis in patients who have had an inadequate response to one or more
disease-modifying antirheumatic drugs ("DMARDs"). The approval of ENBREL ends
the risk that the Company would be required to write-off the amounts recorded as
inventory of ENBREL and any related purchase commitments due to the product not
being approved by the FDA.
DEPRECIATION AND AMORTIZATION
Depreciation of buildings, equipment and capital leases is calculated using the
straight-line method over the estimated useful lives of the related assets which
range from 3 to 31.5 years. Leasehold improvements are amortized on a straight-
line basis over the lesser of the estimated useful life or the term of the
lease. The costs of acquiring leasehold interests are amortized over the
remaining term of the lease.
REVENUES
Product sales are recognized when product is shipped. The Company performs
ongoing credit evaluations of its customers and does not require collateral.
Product sales are recorded net of reserves for estimated chargebacks, returns,
discounts, Medicaid rebates and administrative fees. The Company maintains
reserves at a level which management believes is sufficient to cover estimated
future requirements.
Revenues received under royalty, licensing and contract manufacturing agreements
are recognized based on the terms of the underlying contractual agreements.
NOTE 3. REPORTING COMPREHENSIVE INCOME
As of January 1, 1998, the Company adopted Statement of Financial Accounting
Standards ("SFAS") No. 130, "Reporting Comprehensive Income." SFAS No. 130
establishes new rules for the reporting and display of comprehensive income and
its components; however, the adoption of this statement had no impact on the
Company's financial position or results of operations.
9
<PAGE>
IMMUNEX CORPORATION
Notes to Consolidated Financial Statements (continued)
NOTE 3. REPORTING COMPREHENSIVE INCOME (CONTINUED)
SFAS No. 130 requires unrealized gains or losses on the Company's available-for-
sale securities to be included in comprehensive income. For quarterly reporting
purposes, the following table sets forth the components of comprehensive income
(loss), (in thousands):
<TABLE>
<CAPTION>
Three months Three months Nine months Nine months
ended ended ended ended
September 30, September 30, September 30, September 30,
1998 1997 1998 1997
------------- ------------- ------------- -------------
<S> <C> <C> <C> <C>
Net income (loss) $(4,925) $ 6,199 $(13,755) $(11,201)
------- ------- -------- --------
------- ------- -------- --------
Unrealized gain (loss) on
investments, net of
reclassification adjustment (237) 7,051 (3,266) 2,536
------- ------- -------- --------
Comprehensive income (loss) $(5,162) $13,250 $(17,021) $ (8,665)
------- ------- -------- --------
------- ------- -------- --------
</TABLE>
NOTE 4. EARNINGS PER COMMON SHARE
As of December 31, 1997, the Company adopted SFAS No. 128, "Earnings per Share."
The Statement replaced the previously reported primary and fully diluted
earnings per share with basic and diluted earnings per share. Basic earnings
per share is calculated using the weighted average number of common shares
outstanding. Diluted earnings per share is computed on the basis of the
weighted average number of common shares outstanding plus the effect of dilutive
outstanding stock options using the "treasury stock" method. The components of
calculating earnings (loss) per share is set forth in the following table (in
thousands, except per share data):
<TABLE>
<CAPTION>
Three months Three months Nine months Nine months
ended ended ended ended
September 30, September 30, September 30, September 30,
1998 1997 1998 1997
------------- ------------- ------------- -------------
<S> <C> <C> <C> <C>
Net income (loss) $(4,925) $ 6,199 $(13,755) $(11,201)
------- -------- -------- --------
------- -------- -------- --------
Weighted average common
shares outstanding, basic 39,898 39,645 39,820 39,622
Net effect of dilutive stock
options - 2,069 - -
------- -------- -------- --------
Weighted average common
shares outstanding, diluted 39,898 41,714 39,820 39,622
------- -------- -------- --------
------- -------- -------- --------
Earnings (loss) per common
share, basic $ (0.12) $ 0.16 $ (0.35) $ (0.28)
------- -------- -------- --------
------- -------- -------- --------
Earnings (loss) per common
share, diluted $ (0.12) $ 0.15 $ (0.35) $ (0.28)
------- -------- -------- --------
------- -------- -------- --------
</TABLE>
10
<PAGE>
IMMUNEX CORPORATION
Notes to Consolidated Financial Statements (continued)
NOTE 6. SUBSEQUENT EVENT
On November 2, 1998, the Company received FDA approval to market ENBREL in the
United States. ENBREL is indicated for reduction in signs and symptoms of
moderately to severely active rheumatoid arthritis in patients who have had an
inadequate response to one or more DMARDs. Under the terms of an Enbrel
Promotion Agreement ("Promotion Agreement") with AHP dated September 25, 1997,
the Company earned a $30.0 million scheduled payment upon approval by the FDA.
In accordance with the terms of the Promotion Agreement, the payment is
due in December 1998, thirty days subsequent to the date of such FDA approval.
The revenue will be reported as royalty and contract revenue in the fourth
quarter of 1998.
11
<PAGE>
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
INTRODUCTION
The following discussion of results of operations, liquidity and capital
resources includes certain forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. The
words "believes," "anticipates," "expects" and similar expressions are intended
to identify such forward-looking statements, but their absence does not mean a
statement is not forward-looking. Such statements are based on current
expectations and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those anticipated by the statements
made by Immunex. Certain risk factors have been identified which could affect
the Company's actual results and are described in the Company's latest Annual
Report on Form 10-K filed with the Securities and Exchange Commission. Readers
are cautioned not to place undue reliance on these forward-looking statements
which speak only as of the date of this report. The Company undertakes no
obligation to publicly release the result of any revisions to these forward-
looking statements that may be made to reflect events or circumstances after the
date of this report or to reflect the occurrence of unanticipated results.
RESULTS OF OPERATIONS
OVERVIEW
For the three months ended September 30, 1998, the Company incurred a net
loss of $4.9 million versus net income of $6.2 million for the comparable 1997
period. For the nine months ended September 30, 1998 and 1997, the Company
incurred net losses of $13.8 million and $11.2 million, respectively. Operating
results for the current year periods reflect growth in product sales, primarily
from increased demand for LEUKINE-Registered Trademark- (sargramostim), and
increased operating expenses including the acquisition of product rights outside
the United States, Canada and Puerto Rico ("North America") to four receptor-
based products in April 1998 for $10.0 million, the cost of which was expensed
as in-process research and development. In addition, in September 1997, the
Company and AHP entered into a Promotion Agreement for ENBREL. The Company
earned $15.0 million in September 1997 upon signing of the Promotion Agreement
and earned an additional $20.0 million in June 1998, following the acceptance
for review by the FDA of the Company's Biologics License Application ("BLA") for
ENBREL for treatment of advanced rheumatoid arthritis. On November 2, 1998, as
previously indicated, the Company received FDA approval to market ENBREL in the
United States. The Company earned $30.0 million under the Promotion Agreement
for ENBREL upon such FDA approval. The revenue will be reported as royalty and
contract revenue in the fourth quarter of 1998.
REVENUES
Product sales increased to $40.1 million from $37.7 million and to $118.9
million from $112.5 million for the three and nine months ended September 30,
1998 and 1997, respectively. The improvement during both 1998 periods is due
primarily to increased sales of LEUKINE. Demand for LEUKINE continues to
increase, representing expansion of the customer base primarily in the
outpatient setting. For the three and nine-month periods ended September 30,
1998, sales of LEUKINE totaled $17.0 million and $48.3 million, respectively,
versus $14.1 million and $39.6 million for the comparable 1997 periods. Sales
of NOVANTRONE-Registered Trademark- (mitoxantrone) have leveled following an
initial increase in demand after the product received an expanded label
indication in late 1996. Sales of NOVANTRONE totaled $13.0 million and $39.4
million for the three and nine months ended September 30, 1998, respectively,
compared to $13.4 million and $37.9 million for the respective 1997 three and
nine-month periods.
12
<PAGE>
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (continued)
Beginning in the second half of 1997, the Company's sales force began promoting
THIOPLEX-Registered Trademark- (thiotepa for injection), contributing to year-
to-date growth in sales of THIOPLEX to $17.1 million in 1998 compared to $16.4
million for the nine months ended September 30, 1997. Sales of THIOPLEX in the
third quarter of 1998 approximated the 1997 third quarter sales level.
The increased sales, discussed above, were partially offset by decreased
sales of leucovorin calcium. Leucovorin calcium has experienced declining sales
volume and selling prices as a result of generic competition. The decline in
sales was accelerated during 1997 following the entry of an additional
competitor into the leucovorin calcium market. As a result, sales of leucovorin
calcium decreased to $1.0 million and $3.6 million during the three and nine
months ended September 30, 1998, respectively, versus $1.6 million and $7.4
million for the comparable 1997 periods. The trend of declining sales of
leucovorin calcium is not expected to reverse itself over the long-term. In
addition to decreased sales of leucovorin calcium, in December 1997 the Company
sold its rights to certain oncology products in Canada to Lederle Parenterals,
Inc., a wholly owned subsidiary of AHP. Accordingly, the Company is no longer
generating product sales from this business in Canada.
Royalty and contract revenue decreased to $9.1 million from $18.3 million
for the quarters ended September 30, 1998 and 1997, respectively. For the nine-
month periods ended September 30, 1998 and 1997, royalty and contract revenue
increased to $36.3 million from $25.9 million, respectively. Royalty and
contract revenue has fluctuated significantly during both 1998 and 1997 as a
result of revenues earned under the Promotion Agreement for ENBREL. As
discussed above, the Company earned $15.0 million in September 1997 upon signing
of the Promotion Agreement. The Company earned an additional $20.0 million
under the Promotion Agreement in June 1998, following the acceptance for review
by the FDA of the Company's BLA for ENBREL for treatment of advanced rheumatoid
arthritis. In June 1998, the Company entered into an agreement for the sale of
the Company's Abbreviated New Drug Application for paclitaxel injection, a
generic form of TAXOL-Registered Trademark-, to IVX BioScience, Inc. The
agreement became effective in the third quarter of 1998 following the pre-
acquisition review by the United States Federal Trade Commission and completion
of certain closing conditions. The sale generated revenues of $6.0 million in
the third quarter of 1998 from license fees and sale of paclitaxel inventory.
OPERATING EXPENSES
Cost of product sales was $7.2 million, or 18.0% of product sales and $6.2
million, or 16.5% of product sales for the quarters ended September 30, 1998 and
1997, respectively. For the nine months ended September 30, 1998 and 1997, cost
of product sales was $22.0 million, or 18.5% of product sales and $18.7 million,
or 16.6% of product sales, respectively. The increase in the cost of sales
percentage during 1998 is due primarily to the change in the mix of product
sales to include a relatively higher percentage of sales of LEUKINE and an
increase in period costs charged to cost of product sales in the current year.
The cost of LEUKINE, as a percentage of product sales, is higher than the cost
of NOVANTRONE and THIOPLEX. Accordingly, as sales of LEUKINE have increased,
the overall cost of sales percentage has also increased. In addition, the cost
of LEUKINE has increased during 1998 as compared to the prior year. In January
1998, the Company reached a settlement with the remaining party to an ongoing
GM-CSF patent interference proceeding. In accordance with the settlement,
beginning in January 1998, the Company began incurring additional royalties
payable on net sales of LEUKINE. Also, as part of the resolution of the GM-CSF
patent interference, the Company made a one-time payment of $5.0 million to
Genetics Institute, Inc. ("G.I."), a wholly owned subsidiary of AHP. The $5.0
million payment was capitalized as a cost of acquired product rights and is
being amortized to cost of product sales over the estimated life of LEUKINE.
The increase in the Company's cost of sales percentage was partially offset by
the effect of decreased sales of leucovorin calcium. Leucovorin calcium has a
higher cost of sales
13
<PAGE>
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
percentage than the Company's other products as a whole. As a result, the
declining sales volume of leucovorin calcium has had a favorable impact on the
Company's gross margin.
Research and development expense decreased to $26.9 million from $28.0
million for the three months ended September 30, 1998 and 1997, respectively.
The decrease in expenses during the third quarter of 1998 reflects the
termination of the Company's oncology collaboration and research agreement with
AHP effective July 1, 1998, discussed below. The Company incurred expenses
under this research agreement totaling $4.1 million during the third quarter of
1997. As a result of the termination of this research agreement effective July
1, 1998, no such expenses were incurred during the third quarter of 1998. In
addition, spending on development of CD40 Ligand has decreased due to decreased
manufacturing of clinical materials. These expense decreases were partially
offset by increased spending on development of NUVANCE-TM- (IL-4 receptor) due
to increased manufacturing of clinical requirements of the product and
progression of Phase II clinical trials of NUVANCE for treatment of asthma.
Spending on development of MOBIST-TM- (Flt3-Ligand) also increased during the
third quarter of 1998 and the Company is incurring increased discovery research
expenses and increased development costs associated with preclinical product
candidates. Although research and development spending on ENBREL remains
significant, expense levels for ENBREL during the third quarter of 1998
decreased slightly from expense levels during the third quarter of 1997. The
change reflects decreased manufacturing of clinical product during the third
quarter of 1998 offset by increased development spending by AHP for clinical
studies in Europe, the costs of which are shared equally between Immunex and
AHP.
For the nine-month periods ended September 30, 1998 and 1997, research and
development expense increased to $90.7 million from $78.7 million, respectively.
The increase is due primarily to the acquisition of ex-North American rights to
IL-4 receptor, the IL-1 receptors and IL-7 receptor for $10.0 million in April
1998 from Hoechst Marion Roussel Inc. The cost of the acquisition was expensed
as in-process research and development. In addition to this one-time expense,
spending on development of NUVANCE and MOBIST has increased during 1998 and the
Company has increased spending for discovery research and process development
for its preclinical product candidates, as discussed above. Year-to-date
development costs for ENBREL are also higher in 1998 than 1997 due primarily to
increased expenditures for clinical studies, regulatory expenses associated with
filing of the BLA for ENBREL and increased spending by AHP for development of
ENBREL in Europe, the costs of which are shared equally between Immunex and AHP.
These expense increases were partially offset by decreased clinical expenses for
LEUKINE due to the completion of certain studies during 1997 and decreased
spending on development of CD40 Ligand, discussed above.
In July 1998, Immunex and AHP announced they had ended their oncology
collaboration by terminating their research agreement and certain other
agreements and had entered into a new Product Rights Agreement (the "Product
Rights Agreement"). Under the terms of the superseded research agreement,
Immunex was funding 50% of AHP's oncology discovery research expenditures up to
approximately $16.5 million in 1998 and adjusted annually for inflation
thereafter. In exchange, Immunex had certain rights to AHP's cancer product
candidates in North America. Under the terms of a related agreement that has
also been terminated, AHP held ex-North American rights to new cancer products
resulting from Immunex research. As a result of the termination of the research
agreement, Immunex's funding requirements for AHP oncology discovery research
ceased effective July 1, 1998, thereby eliminating $8.3 million of previously
committed spending over the last half of 1998. In addition, as a result of the
Product Rights Agreement, each party's territorial rights to the other party's
cancer products was terminated. Under the terms of the Product Rights
Agreement, AHP may acquire exclusive worldwide rights to up to four future
Immunex product candidates after such products reach
14
<PAGE>
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
Investigational New Drug ("IND") status. If AHP exercises its rights under the
Product Rights Agreement, Immunex would be eligible for certain payments and
royalties on future worldwide sales of such products. However, Immunex may
elect to retain the worldwide rights to up to two of such products. In such
case, AHP would be eligible for certain payments and royalties on future
worldwide sales of such products. Additional details of the Product Rights
Agreement are set forth in a Current Report on Form 8-K dated July 1, 1998 that
was filed by the Company with the Securities and Exchange Commission.
Selling, general and administrative expense increased to $21.6 million from
$16.5 million and to $60.8 million from $54.4 million for the three and nine-
month periods ended September 30, 1998 and 1997, respectively. Beginning in the
second quarter of 1998, Immunex and AHP began increasing spending on pre-launch
marketing activities for ENBREL. Under the terms of the Promotion Agreement,
AHP has assumed a majority of the pre-launch commercial expenses. The Company's
obligation for such expenses totaled $1.1 million in the third quarter of 1998
and $2.3 million for the nine months ended September 30, 1998. The Company has
also added a staff of Medical Science Liaisons whose role will be to increase
awareness and understanding of ENBREL in the medical community in the United
States. These costs will be shared with AHP following the launch of ENBREL, but
were not shared with AHP in the third quarter of 1998. Selling and marketing
expense for the Company's existing products increased during the third quarter
of 1998, as compared to the prior year. However, for the first nine months of
1998, selling and marketing expenses have decreased moderately from the
comparable period in 1997. General and administrative expenses have also
contributed to the expense increase for both the three and nine-month periods
ended September 30, 1998. The increase is due primarily to expenditures related
to overall growth of the Company and reflects increased spending on information
systems through both increased staffing levels and depreciation expense on
purchases of computer hardware and software. In addition, rent and facilities
expense has increased due to additional office space that was leased beginning
in the second quarter of 1998. The Company has also increased spending in
connection with patent procurement and patent defense activities.
OTHER INCOME (EXPENSE)
Interest income increased to $1.8 million and $4.9 million for the three
and nine months ended September 30, 1998, respectively, compared to $1.1 million
and $2.8 million for the comparable periods in 1997. The improvement reflects
an increase in funds available for investment purposes and the interest earned
therefrom. The Company's cash and marketable securities increased significantly
beginning in early 1997 due primarily to payments received from AHP as
settlement of their 1996 and 1997 revenue shortfall obligations ("Revenue
Guaranty") and improvements in the Company's operating results.
LIQUIDITY AND CAPITAL RESOURCES
Cash, cash equivalents and marketable securities totaled $130.4 million and
$86.5 million at September 30, 1998 and December 31, 1997, respectively. The
Company's cash reserves are held in a variety of interest-bearing instruments
including government and corporate obligations.
Operating activities provided cash of $6.1 million during the first nine
months of 1998, due largely to favorable changes in the Company's working
capital requirements. The Company is due $30.0 million in the fourth quarter
of 1998 that was earned under the Promotion Agreement with AHP following FDA
approval of ENBREL on November 2, 1998, discussed above. However, significant
cash outflows will be incurred for the purchase of inventory of ENBREL and for
the initial launch and sale of ENBREL, discussed below.
15
<PAGE>
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
Capital expenditures increased to $25.9 million for the nine months ended
September 30, 1998. In April 1998, the Company acquired property in the
vicinity of its corporate headquarters for possible development and relocation
of its corporate offices and research facilities. The cost of the property
totaled approximately $15.0 million. Spending on other capital equipment has
also increased during 1998. Beginning in 1998, capital expenditures increased
beyond what had traditionally been a maintenance level of investment, primarily
due to investments in computer systems and research equipment. The Company is
expanding its process development capacity in order to improve its ability to
maximize its product pipeline opportunities. The project to construct a new
process development facility is currently in the design phase and construction
is expected to begin in mid 1999. In addition to the expenditures for property
and equipment, the Company made a payment of $5.0 million to G. I. in January
1998, in accordance with the GM-CSF patent interference, discussed above.
Financing activities provided cash of $68.1 million for the nine-month
period ended September 30, 1998. The Company received $60.0 million from AHP in
February 1998 as payment of the 1997 Revenue Guaranty. This payment was the
final AHP Revenue Guaranty payment. In addition, the Company received $7.2
million from the exercise of employee stock options and the issuance of common
stock to AHP. Under the terms of a 1993 governance agreement with AHP (the
"Governance Agreement"), AHP has the option to purchase from the Company on a
quarterly basis, additional shares of the Company's common stock to the extent
necessary to maintain its percentage ownership interest as of the immediately
preceeding quarter. The per share purchase price of such shares is equal to the
fair market value of such shares, as determined in accordance with the
Governance Agreement, on the date of AHP's purchase. Through the first nine
months of 1998, the Company has issued 71,365 shares of common stock to AHP in
exchange for $4.6 million. AHP exercised this option again in October 1998, and
accordingly, the Company issued an additional 39,918 shares of common stock to
AHP for $2.3 million.
On November 2, 1998, the Company received FDA approval to market ENBREL in
the United States and therefore, earned the $30.0 million scheduled payment
under the Promotion Agreement with AHP. ENBREL is indicated for reduction in
signs and symptoms of moderately to severely active rheumatoid arthritis in
patients who have had an inadequate response to one or more DMARDs. The launch
of ENBREL will have a significant impact on the Company's statement of
operations in the fourth and future quarters and will make comparison to
historical results difficult. Spending on selling and marketing activities will
increase significantly to support the initial launch and subsequent selling,
marketing and distribution of ENBREL. Furthermore, under the terms of the
Promotion Agreement, the Company will be incurring a portion of AHP's sales
force expenses related to ENBREL and will be sharing a percentage of the gross
profits from the sale of ENBREL with AHP. The sale of ENBREL, beginning in
the fourth quarter of 1998, will also have a significant impact on product
sales and cost of product sales. In September 1998, the Company recorded $3.1
million of inventory of ENBREL and a corresponding liability to the contract
manufacturer of ENBREL. The Company has also made significant purchase
commitments to the contract manufacturer for inventory of ENBREL totaling
approximately $104 million at September 30, 1998. Certain risk factors have
been identified that could affect the Company's ability to commercialize
ENBREL and are described in the "Risk Factors" section in the Company's latest
Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Existing cash, cash equivalents and marketable securities are believed to
be sufficient to support the Company's operating requirements and planned
capital expenditures through 1999. Beyond 1999, the Company intends to rely on
accumulated cash reserves and cash generated from operations, which will be
highly dependent on sales of ENBREL and its other products and the successful
development and commercialization of the Company's product candidates and
research technology.
16
<PAGE>
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
YEAR 2000
The "Year 2000" issue is the result of computer programs being unable to
differentiate between the year 1900 and the year 2000 because they were written
using two digits rather than four to define the applicable year. This could
result in a system failure or miscalculations with respect to current programs.
The Company has initiated a comprehensive review of its computer systems and
equipment that utilize date sensitive computer chips, security systems and other
applications that could be affected by the Year 2000 issue. Based on this
review, the Company has determined that certain software and hardware will have
to be modified or replaced so that those systems will properly utilize dates
beyond December 31, 1999. Furthermore, the Company has initiated contact with
key third party suppliers, service providers, distributors, wholesalers and
other entities with which it has a business relationship ("Business Partners")
to address their compliance with Year 2000 requirements. The Company anticipates
that required modifications and replacements of its critical systems and
applications will be completed prior to the year 2000. However, if such
modifications are not completed by the Company in a timely manner, or if there
were a similar such failure on the part of the Company's Business Partners,
there could be a material adverse impact on the operations of the Company.
The Company's plan to resolve the Year 2000 issues is organized into three
functional areas: Information Technology, Embedded Chips and Business Partners.
For each functional area, there are three phases: Phase I: Assessment; Phase II:
Testing and Remediation; and Phase III: Implementation and Contingency Planning.
A substantial portion of the Phase I activities for Information Technology and
Embedded Chips is complete and various testing and remediation projects are in
process. The Company is interviewing its Business Partners to assess Year 2000
readiness. Progress of its Business Partners to become Year 2000 compliant will
be monitored and remediation and contingency planning will be made as needed.
The estimated completion dates of each phase of the three functional areas are
as follows:
<TABLE>
<CAPTION>
- ---------------------------------------------------------------------------------
Information
Technology Embedded Chips Business Partners
- ---------------------------------------------------------------------------------
<S> <C> <C> <C>
Phase I 1998 Fourth Quarter 1999 First Quarter 1999 First Quarter
- ---------------------------------------------------------------------------------
Phase II 1999 Second Quarter 1999 Second Quarter 1999 Second Quarter
- ---------------------------------------------------------------------------------
Phase III 1999 Third Quarter 1999 Third Quarter 1999 Third Quarter
- ---------------------------------------------------------------------------------
</TABLE>
The Company is utilizing both internal and external resources to identify,
correct and test its computer systems for Year 2000 compliance. The Company's
total cost of the Year 2000 project is estimated at approximately $6.0 million
($1.5 million expensed and $4.5 million capital). Through September 30, 1998,
the Company has incurred approximately $1.1 million ($0.4 million expensed and
$0.7 million capital). These costs do not include any internal costs.
The Company has not identified its most reasonably likely worst case
scenario with respect to possible losess in connection with Year 2000 related
problems. The Company plans on completing this analysis in mid 1999. The
Company has not begun the contingency planning process. Contingency plan
development is scheduled for completion in the second half of 1999.
17
<PAGE>
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
The Year 2000 disclosures discussed above are based on numerous
expectations which are subject to uncertainties. Certain risk factors which
could have a material adverse effect on the Company's results of operations
and financial condition include but are not limited to: failure to identify
critical systems which will experience failures, errors in the remediation
efforts, unexpected failures by key Business Partners, inability to obtain new
replacements for non-compliant systems or equipment, failures by governmental
agencies causing delays in approval of new products or sales of approved
products, general economic downturn relating to Year 2000 failures in the U.S.
and in other countries, failures in global banking systems and capital
markets, or extended failures by public and private utility companies or
common carriers supplying services to the Company.
18
<PAGE>
PART II. OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
The description of legal proceedings is incorporated by reference to Item 3
of the Company's Annual Report on Form 10-K for the fiscal year ended December
31, 1997.
Item 6. EXHIBITS AND REPORTS ON FORM 8-K
a) Exhibit 27 Financial Data Schedule
b) Reports on Form 8-K
A Current Report on Form 8-K dated July 1, 1998, was filed with the
Securities and Exchange Commission reporting that Immunex Corporation
entered into a Product Rights Agreement with AHP acting through its
Wyeth-Ayerst Research division and with American Cyanamid Company
acting through its Lederle Pharmaceutical division.
19
<PAGE>
SIGNATURES
Pursuant to requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
IMMUNEX CORPORATION
Date: November 12, 1998 /s/ Edward V. Fritzky
-------------------------- --------------------------------------
Edward V. Fritzky
Chairman and Chief Executive Officer
(Principal Executive Officer)
Date: November 12, 1998 /s/ Douglas G. Southern
-------------------------- --------------------------------------
Douglas G. Southern
Senior Vice President, Chief Financial
Officer and Treasurer
(Principal Financial and Accounting
Officer)
20
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 1998, AND THE CONSOLIDATED
STATEMENT OF OPERATIONS FOR THE NINE-MONTH PERIOD ENDED SEPTEMBER 30, 1998, AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> SEP-30-1998
<CASH> 71,414
<SECURITIES> 58,978
<RECEIVABLES> 27,155
<ALLOWANCES> 10,064
<INVENTORY> 9,666
<CURRENT-ASSETS> 4,934
<PP&E> 152,375
<DEPRECIATION> 63,248
<TOTAL-ASSETS> 286,896
<CURRENT-LIABILITIES> 54,636
<BONDS> 0
0
0
<COMMON> 718,701
<OTHER-SE> 492,318
<TOTAL-LIABILITY-AND-EQUITY> 286,896
<SALES> 118,902
<TOTAL-REVENUES> 155,197
<CGS> 22,024
<TOTAL-COSTS> 173,544
<OTHER-EXPENSES> 311
<LOSS-PROVISION> 167
<INTEREST-EXPENSE> 331
<INCOME-PRETAX> (13,505)
<INCOME-TAX> 250
<INCOME-CONTINUING> (13,755)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (13,755)
<EPS-PRIMARY> (0.35)
<EPS-DILUTED> (0.35)
</TABLE>
